Literature DB >> 1525588

Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism.

C Marcocci1, L Bartalena, F Bogazzi, G Bruno-Bossio, A Pinchera.   

Abstract

The relationship between the treatment of Graves' hyperthyroidism and the course of ophthalmopathy is rather unclear. Antithyroid drugs may improve eye manifestations, possibly by restoring normal thyroid function and reducing orbit-directed autoimmune reactions, whereas ophthalmopathy may worsen after radioiodine administration or thyroidectomy. This might occur because of a treatment-related release of thyroid antigens and activation of the autoimmune response that might involve the orbit. On the other hand, some authors suggest that complete thyroid ablation, either by radioiodine or surgery, might be beneficial for ophthalmopathy. However, reported effects of radioiodine and thyroidectomy on Graves' ophthalmopathy are conflicting. This may be due, at least in part, to the retrospective feature of most studies and the lack of precise evaluation of ocular involvement. Two prospective studies were performed in which patients with Graves' disease with mild or no ophthalmopathy were randomly assigned to treatment by radioiodine or subtotal thyroidectomy alone or in association with systemic glucocorticoids. Both treatments were followed by a progression of pre-existing mild ophthalmopathy in a substantial proportion of cases: glucocorticoids prevented such an exacerbation. Ophthalmopathy did not develop in patients without clinical evidence of eye disease prior to therapy. Therefore, it is recommended that a course of glucocorticoids be instituted concomitantly with radioiodine therapy or thyroidectomy in Graves' patients with some degree of ocular involvement.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1525588     DOI: 10.1089/thy.1992.2.171

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  17 in total

Review 1.  Radioiodine and thyroid-associated ophthalmopathy: from the myth to the reality.

Authors:  C Beckers
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  The role of thyroid eye disease and other factors in the overcorrection of hypotropia following unilateral adjustable suture recession of the inferior rectus (an American Ophthalmological Society thesis).

Authors:  Natalie C Kerr
Journal:  Trans Am Ophthalmol Soc       Date:  2011-12

Review 3.  Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid?

Authors:  L Bartalena; C Marcocci; A Lai; M L Tanda
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

Review 4.  Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?

Authors:  C Marcocci; L Bartalena; A Pinchera
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

Review 5.  Thyroid eye disease.

Authors:  D H Char
Journal:  Br J Ophthalmol       Date:  1996-10       Impact factor: 4.638

Review 6.  Total thyroid ablation in Graves' orbitopathy.

Authors:  F Menconi; M Leo; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2015-03-05       Impact factor: 4.256

Review 7.  Prevalence and natural history of Graves' orbitopathy in the XXI century.

Authors:  E Piantanida; M L Tanda; A Lai; L Sassi; L Bartalena
Journal:  J Endocrinol Invest       Date:  2013-04-16       Impact factor: 4.256

8.  Medical management of thyroid eye disease.

Authors:  Dawn D Yang; Mithra O Gonzalez; Vikram D Durairaj
Journal:  Saudi J Ophthalmol       Date:  2010-10-26

Review 9.  Ablative or non-ablative therapy for Graves' hyperthyroidism in patients with ophthalmopathy?

Authors:  A P Weetman; B J Harrison
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

10.  Effect of near-total thyroidectomy on thyroid orbitopathy due to toxic goiter.

Authors:  Yasser A Elsayed; Atif M Abdul-Latif; Mukhtar F Abu-Alhuda; Hosam A-F Halim
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.